Drug WatchTofacitinib Receives New Boxed Safety WarningAschenbrenner, Diane S. MS, RNAuthor Information Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: firstname.lastname@example.org. AJN, American Journal of Nursing: November 2019 - Volume 119 - Issue 11 - p 20 doi: 10.1097/01.NAJ.0000605328.68897.ed Buy Metrics Abstract A new boxed warning has been added to the labeling of tofacitinib (Xeljanz, Xeljanz XR) based on preliminary safety data from an ongoing postmarketing trial showing an increased risk of thrombosis and death in patients with at least one cardiovascular risk factor who were taking the 10-mg twice-daily dose. Tofacitinib 10 mg twice daily is approved as induction treatment for ulcerative colitis; the dose is not approved to treat rheumatoid arthritis or psoriatic arthritis. NPs should adhere to the dosing regimens listed on tofacitinib's labeling. Patients should be assessed for thrombosis and taught to seek emergency help if they develop signs or symptoms of this condition. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.